期刊文献+

辛伐他汀对绝经伴血脂代谢异常女性跟骨骨密度的影响 被引量:1

Effect of simvastatin on bone mineral density of the calcaneus in postmenopausal women with hyperlipoidemia
下载PDF
导出
摘要 目的研究辛伐他汀对绝经后伴血脂代谢异常女性跟骨骨密度的影响。方法分析885名绝经后口服辛伐他汀治疗血脂代谢异常(TC>5.18 mmol/L或LDL-C>3.37 mmol/L)女性的跟骨骨密度,并依据T值分为骨质正常、骨量减少、骨质疏松。结果治疗前跟骨骨密度为305.3±59.2 mg/cm2,骨质正常、骨量减少、骨质疏松的人数分别为115、446、324,口服辛伐他汀(20 mg/d)治疗3月后骨密度为309.7±56.3 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为117、459、319,12月后跟骨骨密度为312.5±60.9 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为122、460、303。结论绝经后伴血脂代谢异常女性应用辛伐他汀(20 mg/d)治疗12个月后跟骨骨密度增高,但对骨质疏松患病风险无影响。 Objective To evaluated the effect of simvastatin on bone mineral density(BMD) of the calcaneus in postmenopausal women with hyperlipidemia.Methods BMD of the calcaneus of 885 postmenopausal women with hyperlipidemia(TC 5.18 mmol /L or LDL-C 3.37 mmol /L) were studied.Simvastatin was used in these women.According to the T-score,normal bone mass,osteopenia,and osteoporosis were diagnosed.Results BMD of the calcaneus was 305.3 ± 59.2 mg /cm2 before the treatment.The number of people with normal bone mass,osteopenia,and osteoporosis were 115,446,and 324,respectively.After simvastatin administration(20 mg /d) for 3 months,the BMD was 309.7 ± 56.3 mg /cm2.The number of people with normal bone mass,osteopenia,and osteoporosis were 117,459,and 319,respectively.After a 12-month treatment,BMD of the calcaneus was312.5 ± 60.9 mg /cm2.The number of people with normal bone mass,osteopenia,and osteoporosis were 122,460,and 303,respectively.Conclusion After a 12-month simvastatin(20 mg /kg·d) administration,BMD of the calcaneus increases in postmenopausal women with hyperlipidemia.It can not affect the risk of osteoporosis for these women.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2014年第10期1236-1239,共4页 Chinese Journal of Osteoporosis
关键词 辛伐他汀 绝经 血脂代谢异常 骨密度 Simvastatin Postmenopausal Hyperlipidemia Bone mineral density
  • 相关文献

参考文献10

二级参考文献85

共引文献67

同被引文献39

  • 1朱剑峰,朱红静,李志辉,王姗姗,罗俊敏.辛伐他汀对绝经期冠心病合并骨质疏松患者骨密度的影响分析[J].中国生化药物杂志,2014,34(6):157-159. 被引量:9
  • 2de Matos MB,Puga AM,Alvarez-Lorenzo C,et aI.Osteogenic poly(E-caprolactone)/poloxamine homogeneous blends prepared by supercritical foaming.lnt J Pharm.2014;479(1): 11-22.
  • 3Wang H, Liu J, Tao S, et al. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.lnt J Nanomedicine.2015;8(10):5671-5685.
  • 4Kwon YD, Yang DH, Lee DW. A Titanium Surface-Modified with Nano-Sized Hydroxyapatite and Simvastatin Enhances Bone Formtion and Osseintegration.J Biomed Nanotechnol. 2015;11(6):1007-1015.
  • 5Oryan A, Kamali A, Moshiri A. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions.J Control Release.2015; 10(215):12-24.
  • 6Chauhan AS, Maria A, Managutti A. Efficacy of Simvastatin in Bone Regeneration After Surgical Removal of Mandibular Third Molars: A Clinical Pilot Study.J Maxillofac Oral Surg. 2015; 14(3):578-585.
  • 7Tan J, Fu X, Sun CG, et al. A single CT-guided percutaneous intraosseous injection of thermosensitive simvastatin/poloxamer 407 hydrogel enhances vertebral bon formation in ovariectomized minipigs.Osteoporos Int.2015; 7(30)112-114.
  • 8Soares EA, Novaes RD, Nakagaki WR, et al. Metabolic and structural bone disturbances induced by hyperlipidic diet in mice treated with simvastatin.lnt J Exp Pathol. 2015;96(4): 261-268.
  • 9Li XF, Lin CB, Xie FR, et al. Effects of Simvastatin and Combination of Simvastatin and Nylestriol on Bone Metabolism in Ovariectomized Rats.Am J Ther.2015;7(9): 112-114.
  • 10Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.N Engl J Med.2015;372(25):2387-2397.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部